SCHEMBL18270538

SCHEMBL18270538

COc1cc2c(cc1O)C(c1cc(OC)c(OC)c(OC)c1)OC(=O)N2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.42
▸ TP53 P04637 1/20 0.40
▸ MAPT P10636 2/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ HPGD P15428 2/20 0.40
▸ CA2 P00918 1/20 0.40
▸ TUBB4A P04350 4/20 0.39
▸ TUBB P07437 4/20 0.39
▸ TUBA3C P0DPH7 4/20 0.39
▸ TUBA1B P68363 4/20 0.39
▸ TUBA4A P68366 4/20 0.39
▸ TUBB4B P68371 4/20 0.39
▸ TUBB3 Q13509 4/20 0.39
▸ TUBB2A Q13885 4/20 0.39
▸ TUBB8 Q3ZCM7 4/20 0.39
▸ TUBA3E Q6PEY2 4/20 0.39
▸ TUBA1A Q71U36 4/20 0.39
▸ TUBA1C Q9BQE3 4/20 0.39
▸ TUBB6 Q9BUF5 4/20 0.39
▸ TUBB2B Q9BVA1 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18270539 0.95 LMNA (0.42) LMNATP53MAPTALDH1A1HPGD
SCHEMBL19669615 0.90 ERN1 (0.38) LMNATP53MAPTALDH1A1HPGD
SCHEMBL18268181 0.87 LMNA (0.38) LMNATP53MAPTALDH1A1HPGD
SCHEMBL18268179 0.85 TP53 (0.40) LMNATP53ALDH1A1CA2KDM4E
SCHEMBL18268205 0.80 ALDH1A1 (0.47) LMNATP53MAPTALDH1A1HPGD
SCHEMBL18268207 0.72 CA2 (0.39) LMNATP53ALDH1A1HPGDCA2
SCHEMBL17001498 0.71 ALDH1A1 (0.40) LMNATP53MAPTALDH1A1HPGD
SCHEMBL18270510 0.71 KDM4E (0.43) MAPTALDH1A1HPGDCA2KDM4E
SCHEMBL18268180 0.69 CA2 (0.44) LMNAMAPTALDH1A1HPGDCA2
SCHEMBL18268186 0.69 KDM4E (0.48) LMNAMAPTALDH1A1HPGDCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3102567-B1 INHIBITORS OF PAXILLIN FUNCTION AND RELATED COMPOSITIONS AND METHODS UNIV TENNESSEE RES FOUND (US) 2019-07-17 — — EP disclosed
US-9834525-B2 Inhibitors of paxillin function and related compositions and methods UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2017-12-05 — — US disclosed
US-20160347725-A1 INHIBITORS OF PAXILLIN FUNCTION AND RELATED COMPOSITIONS AND METHODS UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2016-12-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160347725-A1 INHIBITORS OF PAXILLIN FUNCTION AND RELATED COMPOSITIONS AND METHODS CTTN, PTK2, CDC42 LMNA 797/4885TP53 348/4885MAPT 1918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback